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Advantages of the new loop diuretic torasemide over furosemide in 
patients with cirrhosis and ascites 
A randomized, double blind cross-over trial 
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~Department of Medtcine II and bDepartment of Clinical Chemistry. Klinikum Grosshadern, Umversity of Munich, Munich, Germany 
(Recewed 4 March 1992) 
Torasemide is a new loop diuretic with a longer half-life and longer action than furosemide in healthy subjects. In 
order to evaluate the pharmacodynamic effects, single oral doses of furosemide (80 mg) and torasemide (20 mg), which 
were equipotent in healthy subjects, were given to 14 patients with cirrhosis and ascites. Before the study patients 
underwent an equilibration period of 4 days without diuretics. The drugs were alternated following a randomized 
double-blind cross-over design after a wash-out period of at least 2 days. Urine was collected at defined intervals for 
24 h after drug administration and blood samples were taken before, 6 h and 24 h after medication. Torasemide 
induced greater cumulative 24 h diuresis (2863 + 343 vs. 2111 + 184 ml, p<0.01) than furosemide. Torasemide did 
not differ from furosemide for cumulative 0-6 h sodium excretion (96 -I- 17 vs. 92 + 23 mmol sodium) but caused a 
more pronounced cumulative 6-24 h natriuresis (38 ___ 11 vs. 17 _ 4 mmol, p<0.05). Five patients exhibited a weak 
response to furosemide (0-36 mmol sodium/24 h, median 24 mmol; 690-1460 ml urinary volume/24 h, median 1325 ml). 
These patients howed significantly higher natriuresis and diuresis following torasemide (26-136 mmol sodium/24 h, 
median 78 mmol, p<0.05; 1670-3610 mi urinary volume/24 h, median 2200ml, p<0.05). Twenty-four hours after 
administration f both drugs there were no significant changes in hemodynamic, renal or hormonal parameters. No 
adverse ffects were noted with either treatment. These findings suggest that torasemide might be more advantageous 
than furosemide in the treatment of ascites due to cirrhosis. 
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Introduction 
In cirrhosis with ascites and decreased effective blood 
volume the most commonly used loop diuretic, furose- 
mide, may lead to the activation of sodium retaining 
hormonal systems (1-4), due to its rapid onset and short 
duration of action. Torasemide is a new loop diuretic of 
the pyridine-sulfonamido group (5), which exhibits a 
longer half-life and longer action than furosemide in 
healthy subjects (6). This diuretic has been found to be 
more effective than furosemide on a molar basis and, 
due to its nearly complete bioavailability (7), is equally 
efficient following oral and parenteral dministration. I  
the present study, single oral doses of torasemide and 
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furosemide, which were equipotent in healthy subjects, 
were given to patients with cirrhosis and ascites. Each 
patient was his own control. The aim of this investigation 
was to study the effects and side-effects of torasemide 
compared to the standard loop diuretic, furosemide. 
Patients and Methods 
Fourteen patients with cirrhosis and ascites were 
studied (11 male, 3 female; age 36-66 years, median 53 
years). Diagnosis was based on history, ultrasound, liver 
biopsy and laboratory parameters. The etiology of cir- 
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rhosis was alcoholic in 1 I, posthepatitic in 2 and crypto- 
genic in 1 patient. All patients were non-azotemic (serum 
creatinine levels below 2.0 rag/100 ml), and all serum 
electrolytes were in the normal range. There was no 
evidence of heart failure, renal disease, hypertension, 
diabetes, encephalopathy or recent gastrointestinal 
bleeding. The nature of the study was explained in detail 
to the patients and written consent was obtained. The 
study was designed and performed according to the 
principles of the Declaration of Helsinki and approved 
by the local ethical committee. 
Protocol of the stud), 
The investigation began with an equilibration period 
of at least 4 days without diuretics. Drug administration 
was followed by a 24 h observation period. After a wash- 
out period of at least 2 days and administration of the 
other drug there was another 24 h observation period. 
During the study patients received a regular diet and 
did not receive any other diuretic medication. Baseline 
renal function parameters were investigated in 7 patients 
and were not different before treatment with either drug. 
Single oral doses of torasemide (20 mg) and furosemide 
(80 mg), which were found equipotent in healthy subjects 
(8), were given to patients on the first experimental day 
and alternated on the second day of observation accord- 
ing to a randomized double-blind cross-over design. 
During these days urine was collected at defined intervals 
for 24 h (0-2, 2-4, 4-6, 6-8, 8-10, 10-24 h) and analyzed 
for volume, sodium, potassium and chloride. Blood 
samples for electrolytes, creatinine and other parameters 
were taken before and 24 h after drug administration. 
Blood pressure and heart rate were determined at the 
same time. Blood samples for plasma renin activity and 
plasma aldosterone concentrations were collected under 
basal conditions, 6 and 24 h after administration of the 
diuretic, with patients remaining in the supine position 
for 1 h preceding the collection. Sodium, potassium and 
chloride were determined by flame photometry, creati- 
nine by the conventional colorimetric method of Jaffe, 
and plasma renin activity and plasma aldosterone con- 
centration by a radioenzymatic method as described 
previously (9). 
Statistical analysis 
Results are expressed as the mean and standard error. 
Statistical significance was tested by a paired and 
unpaired Student's t-test, respectively. A p-value of less 
than 0.05 was considered significant. 
Results 
There was no difference in cumulative sodium excre- 
tion between torasemide and furosemide 0-6 h after 
drug administration (Fig. la). However, in the 6-24 h 
interval torasemide induced significantly higher natri- 
uresis (38 _+ II vs. 17 +_ 4mmol sodium)(Table 1). 
Urinary volume was significantly higher following 
torasemide administration (Fig. lb, Table 1), and 
body weight 24 h after administration was reduced by 
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Fig. la. Cumulative urinary sodium excretion m a 24 h period 
following administration f torasemide (20 mg p.o.) (• ) and furosemlde 
(80 mg p.o.) (©) in 14 patients with cirrhosis and ascites. 
Fig. lb. Cumulative urinary volume in a 24 h period following 
administration f torasemide (20 mg p.o.) (O) and furosemide (80 mg 
p.o.) (©) in 14 patients with cirrhosis and ascites. 
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TABLE 1 
Renal effects of torasemide and furosemide in 14 patients with cirrhosis 
and ascites in the intervals 0-6, 6-24 and 0-24 h after administration 
of the drugs 
Torasemide Furosemide 
0-6 h 
UNaV (mmoll 95.7+ 17.2 92.1 _+23.4 
FeNa 1%) 2.2+0.5 2.7-+0.7 
UVol (ml) 1719+211" 1377-+237 
UKV (mmol) 57.5+7.2 39.94-5.5 
UCIV (mmol) 139.7+ 19.9 123.8+22.9 
6-24 h 
UNaV (mmol I 38.4 + 11.3 a 16.6 -+ 4.4 
FeNa ('7~) 0,58-+0.18 0.38+0.14 
UVol (ml) 1144_+ 233" 734_+ 139 
UKV (mmol) 36.0+9.7 27.6-+3.5 
UCIV (mmol) 61.1 -+17.9" 23,3_+6.2 
0-24 h 
UNaV (mmol) 134.0+21.2 I08.5 4- 25.7 
FeNa (%) 1.07_+0.17 1.19-+0.28 
UVol (ml) 2863+351 = 2111 4-351 
UKV (mmol) 88.3 + 10 68.0 + 6.8 
UCIV (mmol) 198.9 _+ 22.9" 143.6 4- 24.6 
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0.49 _ 0.29 kg following furosemid.e and 0.73 + 0.35 kg 3000- 
following torasemide (not significant). 25oo- 
Serum electrolytes and creatinine, blood pressure and 
heart rate were not significantly different 24 h after 2oo0. 
administration of either drug (Table 2). 15oo- 
In relation to the responses to both drugs in individual 
1OOO" 
patients, the 5 patients with the weakest response to 
furosemide showed a markedly greater esponse to tora- 5o0- 
semide: median 24 h sodium excretion 24 vs. 78 mmol o 
(p < 0.05), median 24 h urinary volume 1325 vs. 2200 ml (b) 
(p<0.05) (Table3, Fig. 2a,b). In these patients body 
weight was reduced by torasemide (0.20 _+ 0.77 kg), but 
increased 24 h after furosemide (by 0.12 _+ 0.67 kg). In 
the other 9 patients, compared to furosemide, torasemide 
induced a slight, but not significant increase in natriuresis 
and diuresis (Table 3). The 5 patients who responded 
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Fig. 2a. Twenty-four-hour urinary sodium excretion in 5 patients with 
the poorest response to furosemide (80 mg p.o.) (open bars) and effects 
of torasemide 120 mg p,o.) (hatched bars) in the same patients. 
Fig. 2b. Twenty-four-hour urinary volume in 5 patients with the 
poorest response to furosemide (80 mg p.o.) (open bars) and effects of 
torasemide (20 mg p.o.) (hatched bars) in the same patients. 
TABLE 2 
Serum, hemodynamic and hormonal parameters before and 24 h after administration of torasemide (20 mg p.o.) and furosemide (80 mg p.o.), in 14 
patients with cirrhosis and ascites 
Torasemide Furosemide 
0 h 24 h 0 h 24 h 
Serum parameters 
Sodium (mmol/I) 136+1.1 136___1.1 136+1.2 135+1.1 
Potassium (mmol/l) 3.9+0.14 3.7+0.11 3.9_+0.18 3.9_+0.14 
Creatinine (mg/100 ml) 1.02 _+ 0.06 1.03 _ 0.05 1.07 -+ 0.06 0.99 + 0.06 
Mean arterial pressure 90 4- 3 84 _+ 3.2 88 _+ 4 90 _+ 2.5 
(mmHg) 
Heart rate (rain - J) 82.6 + 2.3 80.8 _+ 2.8 80.9 _+ 3.0 79.1 _+ 1,7 
Plasma renin actwity 29.9 _+ 6 30.6 _+ 6.9 34.7 _+ 7.1 36.8 _+ 7.3 
(ng Ai/ml/h) 
Plasma aldosterone 111.9+33 132_+42.2 105.7_+28.4 131 +44.1 
concentration ( g/100 roll 
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TABLE 3 
Renal effects of torasemide (20 mg p.o.) and furosemide (80 mg p.o.) in the intervals 0-6 h, 6-24 h and 0-24 h in the 5 patients with the weakest 
response to furosemide as compared to the other 9 patients 
Torasemide Furosemide 
n = 5 n = 9 n = 5 n = 9 
0-6 h UNaV (mmol) 48.8 -I- 19.7 ~ 121.8 + 20.2 14 _+ 4.8 a 136 _+ 26.7 
FeNa I%1 1.67 4- 0.8 2.49 4- 0.66 0.5 _ 0.16" 3.98 4- 0.86 
UVol (roll 1292 4-152 1957 _ 295 676 + 133.5 1766 + 289 
UKV (mmol) 63.8 4-15.8 54.1 4- 7.6 30.8 4- 9.8 45 _+ 6.3 
UCIV (mmol) 93.4 + 26 165.4 _ 24 40 _ 13.9" 170 _+ 23 
6-24 h UNaV (mmol) 29.8+19.5 43.1 +14.4 94_4.8 204_6 
FeNa (%) 0.47 4_ 0.28 0.64 4- 0.24 0.49 4- 0.37 0.33 _+ 0. I I 
UVol (ml) 1132_+433 1150+_292 5394-66.8 8424_209 
UK V (mmol) 47.6 _+ 26.4 29.6 _ 5.4 20.9 4- 6.4 31.3 + 3.8 
UCIV (mmol) 56.8 + 35~5 63.4 + 21.4 13.8 + 8.6 28.4 4- 8.1 
0-24 h UNaV (mmol) 78.6 + 2 I, 1 '~ 159.9 + 28.4 22.8 4_ 6.2 ~' 156 + 30 
FeNa (%) 0.83 4- 0.21 1.2 + 0.23 0.3 + 0.09" 1.68 4- 0.33 
U Vol (m I) 2424 + 348 3108 + 506 1215 4- 139 ~ 2609 4- 468 
UKV (mmol) 89.3 + 26~2 87.7+7.7 51.7+ 12.4 77.1 +6.8 
UCIV (mmol) 149.84_25,5 226.1 4_29.8 53.8 4- 20.P 193.64_23.3 
a p<0.05 vs. the subgroup of 9 patients. 
poorly to furosemide did not differ from the other 9 
patients regarding age, renal function or liver function. 
However, these patients did have an increased basal 
heart rate and decreased blood pressure as well as a 
trend towards higher basal plasma renin activity and 
plasma aldosterone concentration (Table 4). 
Discussion 
In our study a double-blind randomized cross-over 
trial was used with each patient as his own control. The 
effects of 20 mg torasemide were compared with those 
TABLE 4 
Characterization of the 5 patients with the weakest response to 
furosemlde and of the 9 other patients investigated 
n=5 n=9 
Sex (male/female) 2/3 
Age (yearsl 55.2 _+ 4.3 
Mean arterial pressure (mmHgl 82.7 +_ 3.2 a 
Heart rate (min- z) 89+ 3 a 
Child-Pugh score 5 B 
Aminopyrin breath test 0,232+0,104 
Prothrombin time (%) 74 4-1 
Serum parameters 
Albumin (g/100 ml) 3.3+0.1 
Bilirubin (mg/100 mll 2.14_+ 0.76 
Creatinine (mg/100 ml) 1.15 + 0.01 
Creatinine clearance Iml/minl 51.3 4-10.7 
Sodium (mmol/ll 132 + 1,2 ~ 
Potassium (mmol/l) 4.1 +0.3 
Plasma renin activity (ng Al/ml/h) 41.2+12 
Plasma aldosterone 
concentration ( g/100 ml) 170+68.4 
9/0 
50.84-3.1 
94.8 +_ 3.3 
78+2 
I A/5 B/3 C 
0.211 _ 0,05 
64+7.5 
3.4+0.1 
2.0 + 0.57 
1.01 -I-0.04 
75.8+10.7 
138__+1 
3.87+0.1 
27.5+7.6 
77.4+17.7 
p<0.05 vs. the subgroup of 9 patients. 
of 80 mg furosemide orally once per day without any 
other diuretic treatment. 
The results of our investigation i dicate that although 
the effects of torasemide were not different from furose- 
mide for natriuresis in the first 6 h following administra- 
tion, torasemide does significantly better in the 6-24 h 
interval. The effects on urinary volume were significantly 
greater for torasemide than for furosemide. The effects 
on plasma renin activity and plasma aldosterone concen- 
tration, however, were not different for the two drugs. 
Therefore, differences in the activation of the renin- 
aldosterone system are not a likely explanation. 
The natriuretic potency of torasemide and furosemide 
in healthy subjects has mostly been investigated with a 
dose ratio of 1:2 on basis of weight (6,12). Whereas in 
these studies the ratio was equipotent, in patients with 
oedema of various origins the ratio shifted to approxi- 
mately 1:8 (13). Studies on patients with cirrhosis and 
ascites used a 1:2 or 1:2.5 ratio of torasemide and 
furosemide (10,11). For the present study we chose a 1:4 
ratio. This was based on two considerations: (a) We 
intended to have a slightly conservative approach and 
use lower torasemide doses relative to the furosemide 
doses than in other studies (6,10-12). (b) In another 
study in healthy subjects using the same protocol with 
20 mg torasemide and 80 mg furosemide we found an 
equal natriuretic and diuretic effect for both doses (8). 
Two studies comparing torasemide with furosemide 
in patients with cirrhosis and ascites have been published 
so far (10,11). The differences in design, however, make 
discussion and comparison of their results with ours 
rather difficult. Brunner et al. compared a single oral 
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dose of 20 mg torasemide to 40 mg furosemide. Unfortu- 
nately the patients had no interval without diuretics 
before the study and received furosemide until the last 
day preceding the investigation. This study does not 
provide information on the administration of aldos- 
terone antagonists, diet or the conditions under which 
the patients were kept preceding the study. Ten patients 
were randomly assigned to the .torasemide and 9 to the 
furosemide group. Both groups differed in age (approx. 
10 years), weight (approx. 5 kg), systolic blood pressure 
(7-12 mmHg) and heart rate (6 bpm). In this investiga- 
tion a longer diuretic action was found for torasemide, 
but there was no difference in urinary volume or sodium 
excretion 24 h after administration of either drug. 
Laffi et al. (1 1) investigated 24 patients with cirrhosis 
and ascites under standard diet hospital conditions, 5 
days after the initiation of a diuretic therapy of 200 mg 
daily of an aldosterone antagonist. The patients were 
then randomly assigned to receive either 25 mg furose- 
mide or 10 mg torasemide orally once a day for 3 days. 
Under these conditions a significantly higher loss of 
body weight and a significant increase in natriuresis 
were observed with the aidosterone antagonist and 
torasemide combination than with the aldosterone 
antagonist and furosemide. 
Our finding that the 5 patients with the weakest 
response to furosemide showed a marked and significantly 
better natriuresis and diuresis after torasemide is of 
particular interest. This is probably not due to cross-over 
effects, since torasemide was given as the first drug in 3 
and furosemide in 2 of these patients. It has been shown 
that activation of the renin-aldosterone system is 
inversely correlated to the renal response to furosemide 
(12,14-16). Indeed the group of 5 patients had a trend 
towards higher plasma renin activity and aldosterone 
concentration before treatment than the other 9 patients 
included in the study. On the other hand, since torasemide 
and furosemide act at the same site of the loop of Henle, 
their effects should be counteracted in the same way by 
any increased sodium retention in the distal tubule. 
It has been shown that the renal effects of furosemide 
are related to a stimulation of renal prostaglandin 
production. In the poor responders to furosemide in our 
study prostaglandin production was possibly increased 
more by torasemide than by furosemide. In a recent 
study (11) torasemide did not affect the urinary excretion 
of prostaglandin metabolites but, due to the limitations 
of a single 24 h urine collection the data of this study 
cannot exclude a role for urinary arachidonic metabolites 
in modulating the natriuretic effects of torasemide. 
Finally, there may be differences in the pharmaco- 
kinetics of these patients, which may account for the 
observed differences in pharmacodynamics (17). In the 
study by Brunner et al. (10) the serum elimination half- 
life of torasemide was longer than that of urosemide in 
patients with cirrhosis and ascites. The possible differ- 
ences in pharmacokinetics for the patients investigated 
in our study remain to be elucidated. Whatever the 
reasons for the differences observed are, the present data 
suggest advantages of torasemide over furosemide partic- 
ularly in patients with cirrhosis and ascites who respond 
poorly to furosemide. If these data are'confirmed by 
long-term treatment studies, torasemide could be pre- 
ferred to furosemide as the loop diuretic of choice in 
these patients. 
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